ArticleAnnals of the rheumatic diseases2022

Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere

No numbers read from the abstract.

Not cited yet